BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

Rhea-AI Summary

BioVie (NASDAQ: BIVI) announced an abstract acceptance for a poster presentation from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease at AD/PD 2026, March 17-21 in Copenhagen.

The poster, “Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (SUNRISE-PD),” summarizes initial enrolled-patient data. Topline results are expected in mid-2026.

Key Figures

AD/PD 2026 dates: March 17–21, 2026

1 metrics

AD/PD 2026 dates March 17–21, 2026 Conference window for SUNRISE-PD abstract poster presentation

Market Reality Check

Price: $1.39 Vol: Volume 47,735 is at 0.49x...

low vol

$1.39 Last Close

Volume Volume 47,735 is at 0.49x the 20-day average of 96,590, indicating subdued trading activity before this update. low

Technical Shares at $1.41 are trading below the $3.44 200-day moving average and remain far under the 52-week high of $13.20.

Peers on Argus

BIVI is up 2.92% while close peers show mixed moves: NERV -4.58%, NXTC +7.34%, B...

1 Up

BIVI is up 2.92% while close peers show mixed moves: NERV -4.58%, NXTC +7.34%, BCTX +13.61%, MTVA +5.5%, IMNN 0%. Momentum scanner only flags PHGE at +2.40% with no news, supporting a stock-specific context.

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Investor webinar	Positive	-0.8%	Announced March 4, 2026 investor webinar discussing bezisterim and BIV201.
Feb 12	Conference abstracts	Positive	-3.5%	Two bezisterim abstracts accepted for American College of Psychiatrists meeting.
Jan 08	Clinical enrollment	Positive	-3.7%	Completed enrollment of 60 patients in Phase 2 SUNRISE-PD Parkinson’s trial.
Nov 19	Investor webinar	Positive	-4.2%	Announced December 9, 2025 webinar covering bezisterim and BIV201 progress.
Sep 26	Investor webinar	Positive	+3.3%	Planned October 8, 2025 webinar with updates on bezisterim and BIV201.

Pattern Detected

Recent company updates, including clinical and investor-focused communications, have often been followed by negative price reactions despite generally constructive or neutral content.

Recent Company History

Over the last few months, BioVie has highlighted bezisterim (NE3107) and BIV201 across webinars and clinical updates. Key milestones included completing enrollment of 60 patients in the Phase 2 SUNRISE-PD trial and scheduling multiple investor webinars to review clinical progress. Abstract acceptances at psychiatric and neurology meetings have also featured bezisterim in Alzheimer’s, Parkinson’s, and Long COVID. Despite these developments, four of the last five news events saw negative 24-hour price moves, indicating a pattern of selling into news.

Market Pulse Summary

This announcement adds incremental visibility for bezisterim (NE3107) by confirming presentation of ...

Analysis

This announcement adds incremental visibility for bezisterim (NE3107) by confirming presentation of SUNRISE-PD baseline data at AD/PD 2026 from March 17–21, 2026. It reinforces ongoing work in early Parkinson’s disease ahead of topline results expected in mid‑2026. Recent history shows multiple webinars and clinical updates around bezisterim and BIV201, so observers may focus on forthcoming efficacy data and regulatory milestones as the next major catalysts.

Key Terms

parkinson’s disease, alzheimer’s disease, clinical trials, neurodegenerative diseases

4 terms

parkinson’s disease medical

"in the treatment of patients with Parkinson’s Disease at the upcoming AD/PD 2026"

A progressive brain disorder that gradually impairs movement, balance and certain mental functions by reducing the brain’s ability to produce a chemical important for controlling motion. Investors care because it creates a large, growing market for treatments, devices and care services; success or failure of drugs and clinical trials, regulatory approvals, and long-term care costs can materially affect pharmaceutical and medical-device company valuations.

alzheimer’s disease medical

"The AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference will present"

A progressive brain disorder that gradually erodes memory, thinking and the ability to perform everyday tasks, similar to a computer slowly losing files and processing speed. It matters to investors because its large and growing patient population drives demand for treatments, long-term care, diagnostics and related services, making clinical trial results, regulatory decisions and patent exclusivity major value drivers for healthcare and biotech companies.

clinical trials medical

"drug development, and clinical trials in Alzheimer’s, Parkinson’s, and other"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

neurodegenerative diseases medical

"developing innovative drug therapies for neurological and neurodegenerative diseases,"

Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.

AI-generated analysis. Not financial advice.

CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming AD/PD 2026 Advances in Science & Therapy annual meeting, to be held March 17-21, 2026 in Copenhagen, Denmark.

The abstract, titled Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD) (J. Palumbo¹, C Ahlem1, C.L. Reading¹, S. O’Quinn², J. Zhang³, M. Stacy⁴), summarizes the initial data on patients enrolled in the SUNRISE-PD study, and will be presented as a poster. Topline results from the SUNRISE-PD study are expected in mid‑2026.

The AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer’s, Parkinson’s, and other related neurological disorders.

Affiliations: ¹BioVie, Inc, ²Perissos, Inc., ³Princeton Pharmatech, ⁴Medical University of South Carolina

About Bezisterim

Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.

In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate-to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid‑2026.

For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.

In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.

About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

For Investor Relations Inquiries:	For Media Inquiries:
Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com	Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations  mweible@elixirhealthpr.com

FAQ

What will BioVie (BIVI) present about bezisterim (NE3107) at AD/PD 2026?

They will present a poster summarizing baseline demographics and participant characteristics for SUNRISE-PD. According to BioVie, the poster details initial enrolled-patient data from the SUNRISE-PD study and will be displayed at the AD/PD 2026 conference in Copenhagen.

When and where is BioVie's SUNRISE-PD poster presented at AD/PD 2026 (BIVI)?

The poster will be presented at AD/PD 2026 in Copenhagen, March 17–21, 2026. According to BioVie, the accepted abstract will appear as a poster session during the conference showcasing SUNRISE-PD baseline data.

What is the title of the SUNRISE-PD abstract BioVie (BIVI) accepted for AD/PD 2026?

The abstract is titled ‘Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (SUNRISE-PD).’ According to BioVie, the listing credits investigators across BioVie, Perissos, Princeton Pharmatech, and Medical University of South Carolina.

When does BioVie (BIVI) expect topline results from the SUNRISE-PD study?

Topline results from SUNRISE-PD are expected in mid-2026. According to BioVie, the company anticipates releasing primary study results around that timeframe following continued enrollment and data collection.

Is the SUNRISE-PD presentation by BioVie (BIVI) a full data readout or an initial summary?

It is an initial summary focusing on demographics and baseline characteristics, presented as a poster. According to BioVie, topline efficacy and full study results remain pending and are expected in mid-2026.